Reata Pharmaceuticals, Inc.
1950 Stemmons Freeway, Suite 5001
67 articles with Reata Pharmaceuticals, Inc.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
The Boston area, specifically Cambridge, has the highest concentration of biopharma companies in the U.S. That is followed rather closely by the San Francisco Bay Area. Many states want to encourage life science development—the return on investment can be very high, and the jobs they create are o...
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in IgA Nephropathy and Type 1 Diabetic Chronic Kidney Disease
Statistically Significant Improvement in Kidney Function Observed in Both Diseases After 12 Weeks of Treatment
Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases.
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
The two-year duration of sustained eGFR improvement in LARIAT is twice as long as Reata has previously reported for bardoxolone.
Reata Announces the Publication of Efficacy Data From the Beacon Study of Bardoxolone in Diabetic CKD in the American Journal of Nephrology
The publication complements previously published safety analyses and reports efficacy analyses that characterize bardoxolone’s longer-term effects on kidney function.
Reata Pharmaceuticals Presents Interim Phase Ib Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma
The data were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Immuno Oncology Congress 2017.
The Company incurred operating expenses of $24.6 million for the quarter ended September 30, 2017, with research and development accounting for $18.3 million.
Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting
Conference call to update bardoxolone renal program today at 8:30am ET.
Reata Announces First Patient Enrolled in Part II of MOXIe Study of Omaveloxolone for the Treatment of Friedreich's Ataxia
The trial will enroll approximately 100 FA patients randomized evenly to either 150 mg of omaveloxolone or placebo.
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Omaveloxolone For The Treatment Of Malignant Melanoma
Reata Pharmaceuticals, Inc. Release: FDA Confirms That Use Of mFARS As Primary Endpoint In Part 2 Of The MOXIe Trial Can Support Approval Of Omaveloxolone In Friedreich’s Ataxia
Reata Pharmaceuticals, Inc. Announces Closing Of Class A Common Stock Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
Reata Pharmaceuticals, Inc.’s Bardoxolone Methyl Demonstrated Improved Kidney Function In Patients With Alport Syndrome In Ongoing Phase II Portion Of Phase II/III Cardinal Study
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Bardoxolone Methyl For The Treatment Of Alport Syndrome
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Omaveloxolone For The Treatment Of Friedreich’s Ataxia